Dexcom (DXCM) Accumulated Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Accumulated Expenses data on file, last reported at $2.1 billion in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 1771.75% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 1771.75% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 1635.71% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.1 billion, up from $1.9 billion in the prior quarter.
• Over the last five years, Accumulated Expenses for DXCM reached as high as $2.1 billion in Q1 2026 and fell as low as $94.8 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $713.1 million across 5 years, with a median of $170.2 million in 2025.
• Across the five-year window, Accumulated Expenses sank 92.34% in 2025 and surged 1771.75% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $134.3 million in 2022, then surged by 901.86% to $1.3 billion in 2023, then plunged by 91.68% to $112.0 million in 2024, then soared by 1635.71% to $1.9 billion in 2025, then rose by 6.68% to $2.1 billion in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.1 billion in Q1 2026, $1.9 billion in Q4 2025, and $170.2 million in Q3 2025.